GIPR and cancer: Recent studies involving paired administration of both incretins—GIP and GLP1— observed that GIP suppressed some adverse behavioral responses to GLP1 (Borner et al., 2021); furthermore, GIPR agonists reduced morphine- and cancer-drug-induced vomiting in ferrets (Asami et al., 2018).